Awards Nomination
20+ Million Readerbase
PMC/PubMed Indexed Articles
Indexed In
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Abstract
CHK1 Inhibitor-Based Checkpoint Abrogation: A Classic, Yet New Therapeutic Approach in Advanced Cancer
Kiyohiro Ando*, Akira Nakagawara, Hiroki Nagase, Shinichi Kobayashi and Satoshi Wada
Recent advances in small molecule kinase inhibitors have markedly improved patient survival in various types of cancer. Most of these successes can be attributed to the concept of “targeting driver oncogenes,” as in the case of tyrosine kinase inhibitors (i.e., EGFR inhibitors), but not in serine/threonine kinase inhibitors including CHK1 inhibitor. Further investigation of the underlying mechanisms is needed to identify synergistic interactions of CHK1 that would help prolong patient survival and improve their quality of life.
Published Date: 2020-05-02; Received Date: 2020-04-13